Induction of Durable Remission in Ocular Inflammatory Diseases

  title={Induction of Durable Remission in Ocular Inflammatory Diseases},
  author={Rene Antonio Cervantes-Casta{\~n}eda and Pooja V. Bhat and E. S. Fortuna and Sarah Acevedo and Christopher S Foster},
  journal={European Journal of Ophthalmology},
  pages={118 - 123}
Purpose To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission. Methods Retrospective cohort study. The records of 399 patients with ocular inflammatory diseases treated with systemic immunomodulatory therapy (IMT) at the Massachusetts Eye Research and Surgery Institution were reviewed. Durable remission was defined as control of inflammation in the absence of systemic IMT for at least 1 year. Fifty patients met the inclusion… 

Tables from this paper

Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report.
Treatment of pediatric uveitis with adalimumab: the MERSI experience.
Road to remission: a comprehensive review of therapy in uveitis
This review serves to highlight important advances in the pharmacologic options available for the treatment of uveitis and ocular inflammation by covering advances in steroid therapy, updates in the clinical safety of systemic immune modulation, and the emerging therapies.
Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis
It is found that methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might prevent AU flares, improve ocular inflammation and visual acuity, and decrease systemic steroids doses.
Emerging therapies for the treatment of uveitis: clinical trial observations
The purpose of this review is to examine the current status of clinical trial observations for newer treatments for uveitis, in addition to novel calcineurin inhibitors, new biologic response modifiers, and other emerging therapies.
University of Birmingham Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis
This document is for the purpose of private study or non-commercial research, and users may not further distribute the material nor use it for the purposes of commercial gain.
Multiple drugs
  • Reactions Weekly
  • 2021


Outcomes of Treatment with Immunomodulatory Therapy in Patients with Corticosteroid-Resistant Juvenile Idiopathic Arthritis-Associated Chronic Iridocyclitis
Improvement or maintenance of visual acuity is noted during the course of follow-up of patients with treatment-resistant JIA-associated uveitis treated with effective IMT, however, only IMT given early in the disease course was noted to be associated with bilateralVisual acuity of 20/30 or better.
Adalimumab in the therapy of uveitis in childhood
For a group of children with long lasting disease the results show that Adalimumab was effective or mildly effective against the arthritis in 81%, but in uveitis in 88%.
Long-term follow-up of intermediate uveitis in children.
Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease.
MMF appears to be a safe and effective second- or third-line adjunct/alternative immunosuppressant in these difficult cases and works well in combination with cyclosporin A, tacrolimus, and antitumor necrosis factor (TNF) agents.
Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use.
Ocular inflammatory disease (OID), with an incidence reported to be as infrequent as 11 to 38 per 100,000 persons per year, is responsible for up to 10% to 15% of all blindness in the United States.
Immunosuppressive therapy for severe chronic uveitis.
Twenty-five patients with severe, progressive, chronic uveitis who were poorly responsive or unresponsive to corticosteroid therapy received low-dose prednisone and cytotoxic immunosuppressive therapy and exhibited a therapeutic response.
Cyclophosphamide therapy of peripheral uveitis.
Clinically significant suppression of inflammation occurred in nine of nine patients with peripheral uveitis and lymphopenia with or without leukopenia correlated best with control of ocular inflammation.
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
Preliminary criteria for inactive disease and clinical remission on and off medication for use in select categories of juvenile idiopathic arthritis (JIA) are formulated using consensus formation techniques.